Schering announces start of three Phase II clinical trials with anti-cancer compound ZK-EPO
European trials will assess ZK-EPO in non-small cell lung, ovarian and breast cancers
02-Dec-2005 -
Schering AG announced the start of three Phase II studies in Europe evaluating its fully synthetic epothilone, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer. The clinical trials will assess ZK-EPO's safety and efficacy ...
breast cancer
clinical trials
Germany
+5